Education
About Us
Working with TipRanks
Follow Us
Oric Pharmaceuticals (ORIC)
NASDAQ:ORIC
ORIC Stock Chart & Stats
Day’s Range― - ―
52-Week Range$3.90 - $14.67
Previous CloseN/A
Volume181.02K
Average Volume (3M)834.38K
Market Cap
$345.90M
Enterprise Value$323.56M
Total Cash (Recent Filing)$59.41M
Total Debt (Recent Filing)$3.18M
Price to Earnings (P/E)―
Beta1.94
Next Earnings
May 12, 2025EPS Estimate
-0.51Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-1.83
Shares Outstanding71,026,825
10 Day Avg. Volume860,936
30 Day Avg. Volume834,384
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)N/A
Price to Sales (P/S)N/A
Price to Cash Flow (P/CF)-4.50
P/FCF Ratio0.00
Enterprise Value/Market Cap0.94
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-2.28
Forecast
1Y Price Target
$18.50Price Target Upside279.88% Upside
Rating ConsensusStrong Buy
Number of Analyst Covering9
---
Oric Pharmaceuticals News
PremiumCompany Announcements
Oric Pharmaceuticals Expands Equity Incentive Plan for Growth
PremiumCompany Announcements
ORIC Pharmaceuticals Reports Progress in Cancer Trials
---
Bulls Say, Bears Say
Bulls Say
Clinical DevelopmentThe initiation of pivotal Phase 3 trials for ORIC-944 and ORIC-114 is expected in 2026, indicating progress in the clinical development of these drugs.
Financial StabilityManagement projects cash runway into 2027, indicating strong financial health to support ongoing research and development.
Market PositionPfizer's data presentation validates the target in prostate cancer and provides opportunities for ORIC as a second to market.
Bears Say
Development RisksRisks include potential inability to advance ORIC-114 and ORIC-944 in clinical development and delays in moving into pivotal trials.
Dilution RiskThere is a long-term dilution risk associated with the company's operations and stock.
Safety ConcernsDespite robust efficacy results, investors focused on the high treatment-related Grade ≥3 adverse event rate of 49%.
---
Ownership Overview
17.56% Insiders
12.40% Mutual Funds
0.25% Other Institutional Investors
58.61% Public Companies and
Individual Investors
Risk Analysis
Main Risk Category
Tech & InnovationRisks related to the company’s reliance on technology and ability to make innovative products
Website Traffic
Sorry, No Data AvailableThere is no website visitor data available for this stock.
---
ORIC FAQ
What was Oric Pharmaceuticals’s price range in the past 12 months?
Oric Pharmaceuticals lowest stock price was $3.90 and its highest was $14.67 in the past 12 months.
What is Oric Pharmaceuticals’s market cap?
Oric Pharmaceuticals’s market cap is $345.90M.
When is Oric Pharmaceuticals’s upcoming earnings report date?
Oric Pharmaceuticals’s upcoming earnings report date is May 12, 2025 which is in 19 days.
How were Oric Pharmaceuticals’s earnings last quarter?
Oric Pharmaceuticals released its earnings results on Feb 18, 2025. The company reported -$0.51 earnings per share for the quarter, missing the consensus estimate of -$0.5 by -$0.01.
Is Oric Pharmaceuticals overvalued?
According to Wall Street analysts Oric Pharmaceuticals’s price is currently Undervalued.
Does Oric Pharmaceuticals pay dividends?
Oric Pharmaceuticals does not currently pay dividends.
What is Oric Pharmaceuticals’s EPS estimate?
Oric Pharmaceuticals’s EPS estimate is -0.51.
How many shares outstanding does Oric Pharmaceuticals have?
Oric Pharmaceuticals has 71,026,825 shares outstanding.
What happened to Oric Pharmaceuticals’s price movement after its last earnings report?
Oric Pharmaceuticals reported an EPS of -$0.51 in its last earnings report, missing expectations of -$0.5. Following the earnings report the stock price went up 1.146%.
Which hedge fund is a major shareholder of Oric Pharmaceuticals?
Currently, no hedge funds are holding shares in ORIC
---
Oric Pharmaceuticals Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Strong Buy
Average Price Target:
$18.50 (279.88% Upside)
$18.50 (279.88% Upside)
Blogger Sentiment
Bullish
ORIC Sentiment 100%
Sector Average 70%
Sector Average 70%
Hedge Fund Trend
Increased
By 204.9K Shares
Last Quarter.
Last Quarter.
Crowd Wisdom
Very Positive
Last 7 Days ▲ 6.7%
Last 30 Days ▲ 6.0%
Last 30 Days ▲ 6.0%
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-47.00%
12-Months-Change
Fundamentals
Return on Equity
-54.73%
Trailing 12-Months
Asset Growth
8.65%
Trailing 12-Months
Company Description
Oric Pharmaceuticals
ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer; and ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms. It has a license and collaboration agreement with Voronoi Inc.; and a license agreement with Mirati Therapeutics, Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.
---
ORIC Stock 12 Month Forecast
Average Price Target
$18.50
▲(279.88% Upside)
Technical Analysis
Celcuity
―
Checkpoint Therapeutics
―
Autolus Therapeutics
―
Sana Biotechnology
―
Erasca
―
Best Analysts Covering ORIC
1 Year
1 Year Success Rate
5/11 ratings generated profit
1 Year Average Return
-6.77%
reiterated a buy rating 3 months ago
Copying Yigal Nochomovitz's trades and holding each position for 1 Year would result in 45.45% of your transactions generating a profit, with an average return of -6.77% per trade.
---